Tango Therapeutics,(TNGX) Investor Presentation - Slideshow

Pipeline and Milestones - Tango Therapeutics expects to initiate a Phase 1/2 trial for TNG462, a next-generation MTA-cooperative PRMT5 inhibitor, in mid-2023[1] - The company plans to file an IND for TNG348, a USP1 inhibitor targeting BRCA1/2 mutant and other HRD+ cancers, in mid-2023[1] - Tango Therapeutics anticipates an initial clinical update for TNG908 in Q2 2023[106] - Tango Therapeutics plans to file an IND for TNG260, a CoREST inhibitor, in the first half of 2023[84, 106] Strategic Partnerships and Financials - Tango Therapeutics has a strong strategic partnership with Gilead[2] - The partnership with Gilead includes $175 million upfront, $20 million in equity, and up to $6 billion in milestones[107] - Tango Therapeutics has sufficient cash to fund operations into 2025[106, 127] Drug Programs and Mechanisms - TNG462 is reported to be approximately 30 times more potent than TNG908 and 45 times more selective for MTAP deletion[10] - TNG462 has an IC50 of 4 nM and 45X selectivity for MTAP deletion[56, 63] - TNG908 is brain penetrant and potentially active in GBM patients[10] - TNG908 demonstrates 15X selectivity for MTAP deletion with an IC50 of 110 nM[35, 163] - TNG260 has an IC50 of 5nM and 10X CoREST complex selectivity[49]